Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 10—October 2010


Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

Scott K. HeysellComments to Author , Jane L. Moore, Suzanne J. Keller, and Eric R. Houpt
Author affiliations: Author affiliations: University of Virginia, Charlottesville, Virginia, USA (S.K. Heysell, E.R. Houpt); Virginia Department of Health, Richmond, Virginia, USA (J.L. Moore, S.J. Keller)

Main Article

Table 2

Comparison of median serum concentration at 2 hours after medication administration as estimate of peak serum concentration levels and expected range, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009*

Medication Median serum concentration, µg/mL (IQR) Expected serum concentration range, µg/mL
Daily 1.9 (1.1–3.5) 3–6
9.8 (2.8–11.2)
Rifampin daily and/or biweekly
7.4 (2.5–11.4)
2.5 (1.7–3.2)
Pyrazinamide† 28.1 (26.5–33.2) 20–50

*IQR, interquartile range.
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these medications.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO